Immunogens derived from SARS-CoV2 spike protein
AssigneeAmgen Inc.
InventorsFernando Garces, Zhulun Wang, Timothy Riley
Life of this patent
Estimating the term…
Abstract
The present invention relates to severe acute respiratory syndrome coronavirus 2 (“SARS-CoV2”) immunogens useful for the generation of therapeutic antibodies and vaccine development. Such therapeutic antibodies include human antibodies and antigen-binding portions thereof that specifically bind to human SARS-CoV2 S protein, and that function to neutralize SARS-CoV2. The present invention also relates to methods of generating antibodies and antigen-binding portions thereof that specifically bind to human SARS-CoV2 S protein.
Claims7
An immunogen comprising a severe acute respiratory syndrome coronavirus 2 spike (“SARS-CoV2 S”) polypeptide, wherein the polypeptide comprises any one of SEQ ID NOs:
- 13-21.
Dependencies are inferred from the claim text.